Malignancy Risk with Belatacept vs. Calcineurin Inhibitors in Kidney Transplant Recipients: Systematic Review and Meta-Analysis TH-PO0196

• Publish Date: 2025-11-05

Research Abstract:

Belatacept-based immunosuppression is associated with a similar risk of SCs and overall malignancy compared to CNI-based regimens. Prior CNI exposure significantly modified the effect of belatacept on skin cancer. Clinicians should be aware of the risk of SCs in belatacept conversion.

Publishers: